Besides, new biomarker-driven immunotherapeutic drugs are being examined, to better select the CC population beyond the programmed death-ligand 1 (PD-L1) status, including cancer therapeutic vaccines targeting E6/E7 oncoproteins for the HPV-related subpopulation, and cell-based strategies targeting specific antigens. Here, CD274 is linked to cancer.